Lupin Launches Thiamine Hydrochloride Injection USP in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of Thiamine Hydrochloride Injection USP, 200 mg/2 mL (100 mg/mL) Multiple-dose Vials, after Lupin's alliance partner Caplin Steriles Limited (Caplin) received an approval for its ANDA from the United States Food and Drug Administration (U.S. FDA).

Thiamine Hydrochloride Injection USP, 200 mg/2 mL (100 mg/mL) Multiple-dose Vials is therapeutically equivalent to the reference listed drug (RLD), Thiamine Hydrochloride Injection USP, 200 mg/2 mL (100mg/mL) of Fresenius Kabi USA LLC.

Thiamine Hydrochloride Injection USP had estimated annual sales of USD 35 million in the U.S. (IQVIA MAT April 2023).

Shares of Lupin Limited was last trading in BSE at Rs. 834.55 as compared to the previous close of Rs. 818.80. The total number of shares traded during the day was 66232 in over 3577 trades.

The stock hit an intraday high of Rs. 835.65 and intraday low of 813.30. The net turnover during the day was Rs. 55075643.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 ThiamineHydrochlorideInjection CaplinSteriles ANDAApproval USFDA